The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.

Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challenge. Thus, we aimed to assess the prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) performed before CDK4/6 inhibitors initiation.

MiRNA in archival serum samples derived from breast cancer patients treated with neoadjuvant chemotherapy vs freshly collected samples: Pilot study.

Background: Liquid biopsy, including miRNA profiling, is a promising approach to identify breast cancer (BC) resistance. However, the effect of long-term storage on the quality of miRNA assessment in archival serum has not been fully addressed.

Objectives: We aimed to determine whether miRNAs were recoverable from long-stored serum samples to subsequently evaluate prognostic and predictive miRNA value in the archival collection of samples from patients treated with neoadjuvant chemotherapy at Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.

Sternotomy and extracorporal circulation for fulminant Budd-Chiari syndrome due to leiomyosarcoma of the inferior vena cava.

Background: Budd-Chiari syndrome is a rare and severe vascular liver disease. We presented patient with fulminant liver failure secondary to leiomyosarcoma of the IVC and thrombosis.

Case Presentation: A 44-year-old female presented with fulminant liver failure secondary to inferior vena cava (IVC) thrombosis.

Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.

Background: In patients diagnosed withestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, bone metastasesemerge as theprimary siteofsignificant tumor burden. Cyclin-dependent kinase 4/6 (CDK4/6i) inhibitorsare thegold standard in this clinical scenario, while radiotherapy (RT) represents a valuable addition. However, data on the efficacy of this combination remain scarce.

The utility of the 21-gene Oncotype DX Breast Recurrence Score assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx.

Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed.